Eton Q2 Revenue Jumps 99% to $37.6M; FY Guide Raised to $145M

For biotech and pharma investors, Eton's Q2 release is not just another small-cap earnings beat—it demonstrates that a commercial rare disease portfolio can generate near-triple-digit growth. The HEMANGEOL relaunch and ASN-001 late-stage addition shape a pump-and-pipeline story that supports raised FY2026 guidance.

The cluster is nominally headlined by Merlin, Inc., but the captured Merlin source page contains only broken JavaScript and no financial data, so no verifiable Merlin results can be reported. The substantive material consists of three Q2 2026 earnings releases published on Aug. 13, 2026: Eton Pharmaceuticals, Dawson Geophysical, and Jefferson Capital. They are unrelated businesses, but together they show how small-cap companies in pharma, energy services, and consumer credit are navigating the 2026 operating environment.

“

Dawson Geophysical, an onshore seismic data acquisition services company, reported second-quarter revenue of $17.9 million, up 82% from $9.9 million in the comparable quarter ended June 30, 2025.

Eton Pharmaceuticals delivered the strongest headline growth. The company reported record second-quarter revenue of $37.6 million, up 99% from $18.9 million in the prior-year period. Management attributed the performance to its rare disease portfolio and pediatric endocrinology franchise. Eton relaunched HEMANGEOL in May 2026 with full Eton Cares patient support, including $0 copay for eligible patients, and licensed ASN-001, a late-stage development program for infantile hemangioma that management said could become the largest revenue opportunity in its pipeline. On the strength of first-half results, Eton raised full-year 2026 revenue guidance to at least $145 million and adjusted EBITDA margin guidance to at least 35%, with the margin target including additional expenses from the ASN-001 transaction and development. CEO Sean Brynjelsen called the quarter outstanding and emphasized the strength of the rare disease portfolio.

The HEMANGEOL relaunch is notable in rare disease because continuity of care and affordability can determine whether infants with infantile hemangiomas receive timely treatment. The company's Eton Cares support program, with $0 copay for eligible patients, is designed to reduce access barriers. ASN-001 adds a late-stage asset that could broaden treatment options, though it is a licensing claim from a company-issued release and carries development expenses that will pressure near-term profitability despite the raised adjusted EBITDA margin target.

Dawson Geophysical, an onshore seismic data acquisition services company, reported second-quarter revenue of $17.9 million, up 82% from $9.9 million in the comparable quarter ended June 30, 2025. Revenue included $3.9 million in reimbursable revenue, up from $1.1 million a year earlier. Gross margin expanded to 19% from 13%. Despite the improvement, the company incurred a net loss of $3.4 million, or $0.11 per common share, and generated adjusted EBITDA of $0.6 million. CEO Tony Clark attributed progress to a significant capital investment in high-channel-count seismic equipment made about a year ago. The company started a high-density channel count job at the end of the second quarter and is investing in compute power to speed data delivery to customers. Clark said the company expects further operational efficiencies and profitability improvements.

Jefferson Capital, an analytically driven purchaser and manager of charged-off, insolvency, and active consumer accounts, did not disclose specific revenue or profit figures in the available snippet, but CEO David Burton said the company delivered excellent performance with consistent momentum across all key aspects of the business. The investment environment remains favorable, according to the release, with auto finance presenting growing portfolio supply due to record high balances and credit quality headwinds. The board declared a quarterly cash dividend of $0.24 per share, payable on September 3, 2026, to shareholders of record as of August 24, 2026.